Joanna Shields, BenevolentAI CEO

AI tools don't equal guar­an­teed drug suc­cess as Benev­o­len­tAI flops der­mati­tis test

It’s a no for BEN.

BEN-2293, a top­i­cal out of Lon­don-based Benev­o­len­tAI, has failed sec­ondary ef­fi­ca­cy mea­sures in a Phase IIa study in atopic der­mati­tis. The in­ves­ti­ga­tion­al drug, one of an ear­ly gen­er­a­tion drummed up by the buzzy AI tools in biotech, works by in­hibit­ing mul­ti­ple tropomyosin-re­lat­ed ki­nas­es, which are known best in the can­cer land­scape with Bay­er’s Vi­t­rakvi and Roche’s Ro­z­lytrek.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters